BIOCRYST PHARMACEUTICALS INC Annual Share-based Payment Arrangement, Expense in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to 2023.
  • Biocryst Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $17.2M, a 40.5% increase year-over-year.
  • Biocryst Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $60.6M.
  • Biocryst Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2023 was $55.6M, a 24.4% increase from 2022.
  • Biocryst Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $44.7M, a 29% increase from 2021.
  • Biocryst Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2021 was $34.6M, a 134% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $55.6M +$10.9M +24.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $44.7M +$10.1M +29% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $34.6M +$19.8M +134% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $14.8M -$2.93M -16.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $17.7M +$8.32M +88.6% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $9.4M -$3.23M -25.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $12.6M +$4.13M +48.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-13
2016 $8.49M -$1.22M -12.6% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 $9.71M -$472K -4.64% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2014 $10.2M +$5.81M +133% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-27
2013 $4.37M +$201K +4.82% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 $4.17M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.